The report – which can be viewed here – highlights the following new medicines: 1) Novo Nordisk's Awiqli (LAI 287; insulin ... fixed-dose combination of an amylin analogue and GLP-1 agonist ...
Adding engineered human blood vessel-forming cells to islet transplants boosted the survival of the insulin-producing cells ...
GLP-1 medications initially were used to help people with diabetes improve their insulin resistance and hunger cravings.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback